PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT00553605
- Locations
- 🇵🇪
Pfizer Investigational Site, Lima, Peru
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 92
- Registration Number
- NCT00551148
- Locations
- 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 386
- Registration Number
- NCT00550446
- Locations
- 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine
Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-DependentHyperglycemia
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00550329
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT00550355
- Locations
- 🇪🇸
Pfizer Investigational Site, Santiago de Compostela, A Coruña, Spain
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00549055
- Locations
- 🇧🇪
Pfizer Investigational Site, Liege, Belgium
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00548093
- Locations
- 🇺🇸
Grady Health Systems, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
Phase 4
Completed
- Conditions
- CandidemiaInvasive Candidiasis
- Interventions
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 54
- Registration Number
- NCT00548262
- Locations
- 🇵🇦
Pfizer Investigational Site, Panama, Panama
Fesoterodine "add-on" Male Overactive Bladder Study
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2011-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 947
- Registration Number
- NCT00546637
- Locations
- 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Chiang Mai, Thailand
First Safety Study in Humans of a Single Dose of CPG 52364
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: 52364 3 mgDrug: 52364 30 mgDrug: 52364 1 mgDrug: 52364 100 mgDrug: 52364 10 mg
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00547014
- Locations
- 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath